Biotech Values

[caravon]

ABBV can't recover from the US DOC the $1.5B break fee it was forced to pay to Shire

Nobody, I repeat, nobody has forced ABBV to pay the $1.5B break fee. It was the result of extremely incompetent and greedy ABBV Sr. management and its Board.

From my old days at ABT, not much has changed, i.e., the same arrogance and obnoxiousness.
--------
(Reuters) - Shares of Gilead Sciences Inc closed down 6 percent on Tuesday, after a pharmacy benefit manager said it would cover both Gilead and rival AbbVie Inc's hepatitis C offering, renewing concerns of pricing pressure.

Investors interpreted this as further discounting of hep C drugs, signaled by an increasing willingness by drugmakers to offer rebates, Sanford Bernstein's Geoffrey Porges wrote in a note.